Tango Therapeutics (Tango Therapeutics) EBIT per Share : $-1.21 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics EBIT per Share?

Tango Therapeutics's EBIT per Share for the three months ended in Dec. 2023 was $-0.34. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.21.

During the past 3 years, the average EBIT per Share Growth Rate was -26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Tango Therapeutics's EBIT per Share or its related term are showing as below:

TNGX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26.4 Med: -26.4 Max: -26.4
Current: -26.4

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Tango Therapeutics was -26.40% per year. The lowest was -26.40% per year. And the median was -26.40% per year.

TNGX's 3-Year EBIT Growth Rate is ranked worse than
79.27% of 1307 companies
in the Biotechnology industry
Industry Median: 3.4 vs TNGX: -26.40

Tango Therapeutics's EBIT for the three months ended in Dec. 2023 was $-35.01 Mil.

Tango Therapeutics EBIT per Share Historical Data

The historical data trend for Tango Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tango Therapeutics EBIT per Share Chart

Tango Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.60

-0.94

-1.27

-1.21

Tango Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial									-0.35	-0.34	-0.26	-0.26	-0.34

Tango Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Tango Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-114.173	/	94.572
=	-1.21

Tango Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-35.013	/	104.485
=	-0.34

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.21

Tango Therapeutics (NAS:TNGX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Tango Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Tango Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Tango Therapeutics (Tango Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215

Website

https://www.tangotx.com

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies.

Executives

Adam Crystal	officer: See Remarks	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
John B Ketchum	director	TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc	director	201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p.	director	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p.	director	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Mva Investors, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron Weitzman	officer: Chief Medical Officer	TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Marc Rudoltz	officer: Chief Medical Officer	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Douglas Barry	officer: See Remarks	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116